Article
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Breast cancer research and treatment - 1 Jul 2012
Santarpia Libero, Qi Yuan, Stemke-Hale Katherine, Wang Bailiang, Young Elliana J, Booser Daniel J, Holmes Frankie A, O'Shaughnessy Joyce, Hellerstedt Beth, Pippen John, Vidaurre Tatiana, Gomez Henry, Valero Vicente, Hortobagyi Gabriel N, Symmans W Fraser, Bottai Giulia, Di Leo Angelo, Gonzalez-Angulo Ana M, Pusztai Lajos
Abstract excerpt
The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from fine needle aspirations of 267 stage I-III breast cancers. These tumor specimens typically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.